Mohamed Hamdani

1.9k total citations · 1 hit paper
29 papers, 770 citations indexed

About

Mohamed Hamdani is a scholar working on Genetics, Hematology and Immunology. According to data from OpenAlex, Mohamed Hamdani has authored 29 papers receiving a total of 770 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 7 papers in Hematology and 7 papers in Immunology. Recurrent topics in Mohamed Hamdani's work include Attention Deficit Hyperactivity Disorder (7 papers), Complement system in diseases (7 papers) and Hemoglobinopathies and Related Disorders (6 papers). Mohamed Hamdani is often cited by papers focused on Attention Deficit Hyperactivity Disorder (7 papers), Complement system in diseases (7 papers) and Hemoglobinopathies and Related Disorders (6 papers). Mohamed Hamdani collaborates with scholars based in United States, United Kingdom and France. Mohamed Hamdani's co-authors include M. Celeste Ferreira‐Cornwell, Robert L. Findling, Maria Gasior, Andrew J. Cutler, Ann Childress, Liza Squires, Jean‐Jacques Kiladjian, Richard H. Weisler, Pascal Deschatelets and Cedric Francois and has published in prestigious journals such as New England Journal of Medicine, Blood and Gastroenterology.

In The Last Decade

Mohamed Hamdani

28 papers receiving 747 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

2021 249 citations Peter Hillmen, Jeff Szer et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Mohamed Hamdani

Since Specialization

Citations

This map shows the geographic impact of Mohamed Hamdani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohamed Hamdani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohamed Hamdani more than expected).

Fields of papers citing papers by Mohamed Hamdani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohamed Hamdani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohamed Hamdani. The network helps show where Mohamed Hamdani may publish in the future.

Co-authorship network of co-authors of Mohamed Hamdani

This figure shows the co-authorship network connecting the top 25 collaborators of Mohamed Hamdani. A scholar is included among the top collaborators of Mohamed Hamdani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohamed Hamdani. Mohamed Hamdani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety, pharmacokinetics, and pharmacodynamics of nomlabofusp (CTI‐1601) in Friedreich's ataxia 2024 ·Annals of Clinical and Translational Neurology ·(unknown), (unknown), (unknown), Jennifer Farmer, Nancy Ruíz, Mohamed Hamdani, (unknown), David Bettoun	10
2	Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan 2021 ·American Journal of Ophthalmology ·Nathan Steinle, Ian Pearce, Jordi Monés, Ravi Metlapally, Namrata Saroj, Mohamed Hamdani, Ramiro Ribeiro, Philip J. Rosenfeld, Eleonora M. Lad	38
3	Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria breakdown → 2021 ·New England Journal of Medicine ·Peter Hillmen, Jeff Szer, Ilene C. Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, Kensuke Usuki, Morag Griffin, Jean‐Jacques Kiladjian, Carlos de Castro, Hisakazu Nishimori, Lisa Tan, Mohamed Hamdani, Pascal Deschatelets, Cedric Francois, F Grossi, Temitayo Ajayi, Antonio M. Risitano, Régis Peffault de la Tour	249
4	Randomized Control Trial of Postnatal rhIGF-1/rhIGFBP-3 Replacement in Preterm Infants: Post-hoc Analysis of Its Effect on Brain Injury 2020 ·Frontiers in Pediatrics ·Sandra Horsch, Alessandro Parodi, Boubou Hallberg, Mariya Malova, Isabella M. Björkman‐Burtscher, Ingrid Hansen‐Pupp, Neil Marlow, Kathryn Beardsall, David B. Dunger, Mirjam M. van Weissenbruch, Lois E. H. Smith, Mohamed Hamdani, Alexandra Mangili, Norman W. Barton, Luca A. Ramenghi, Ann Hellström, David Ley, (unknown)	7
5	CT-286: Results of the PEGASUS Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Carlos de Castro, Peter Hillmen, Jeff Szer, Ilene C. Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, Kensuke Usuki, Morag Griffin, Jean‐Jacques Kiladjian, Hisakazu Nishimori, Lisa Tan, Mohamed Hamdani, Pascal Deschatelets, Cedric Francois, F Grossi, Antonio M. Risitano, Régis Peffault de Latour	1
6	Evaluation of Baseline Factors on Progression in a Large Phase-2 Clinical Trial for Geographic Atrophy (FILLY Study) 2019 ·Investigative Ophthalmology & Visual Science ·Nathan Steinle, Mohamed Hamdani	1
7	Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial 2018 ·Clinical ophthalmology ·Kelly K. Nichols, Edward J. Holland, Melissa Toyos, James H. Peace, Parag A. Majmudar, Aparna Raychaudhuri, Mohamed Hamdani, Monica Roy, Amir Shojaei	19
8	Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis 2017 ·Carolina Digital Repository (University of North Carolina at Chapel Hill) ·Evan S. Dellon, David A. Katzka, Margaret H. Collins, Mohamed Hamdani, Sandeep K. Gupta, Ikuo Hirano	1
9	Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial 2017 ·Journal of Child and Adolescent Psychopharmacology ·Jeffrey R. Strawn, Scott N. Compton, Brigitte Robertson, Anne Marie Albano, Mohamed Hamdani, Moira A. Rynn	38
10	Continuous longitudinal infusion of rhIGF-1/rhIGFBP-3 in extremely preterm infants: Evaluation of feasibility in a phase II study 2017 ·Growth Hormone & IGF Research ·Ingrid Hansen‐Pupp, Ann Hellström, Mohamed Hamdani, (unknown), (unknown), David Ley, Boubou Hallberg	16
11	Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study 2017 ·Haematologica ·Gunnar Birgegård, Carlos Besses, Martin Grießhammer, Luigi Gugliotta, Claire Harrison, Mohamed Hamdani, Jingyang Wu, (unknown), Jean‐Jacques Kiladjian	48
12	953 Safety and Efficacy of Oral Budesonide Suspension for Maintenance Therapy in Eosinophilic Esophagitis: Results From a Prospective Open-Label Study of Adolescents and Adults 2016 ·Gastroenterology ·Evan S. Dellon, David A. Katzka, Margaret H. Collins, Mohamed Hamdani, Sandeep K. Gupta, Ikuo Hirano	8
13	Participant-Perceived Quality of Life in a Long-Term, Open-Label Trial of Lisdexamfetamine Dimesylate in Adolescents with Attention-Deficit/Hyperactivity Disorder 2014 ·Journal of Child and Adolescent Psychopharmacology ·Ann Childress, Andrew J. Cutler, Keith E. Saylor, Maria Gasior, Mohamed Hamdani, M. Celeste Ferreira‐Cornwell, Robert L. Findling	4
14	A Long-Term Open-Label Safety and Effectiveness Trial of Lisdexamfetamine Dimesylate in Adolescents With Attention-Deficit/Hyperactivity Disorder 2013 ·Journal of Child and Adolescent Psychopharmacology ·Robert L. Findling, Andrew J. Cutler, Keith E. Saylor, Maria Gasior, Mohamed Hamdani, M. Celeste Ferreira‐Cornwell, Ann Childress	33
15	Maintenance of Efficacy of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder 2012 ·The Journal of Clinical Psychiatry ·Matthew Brams, Richard H. Weisler, Robert L. Findling, Maria Gasior, Mohamed Hamdani, M. Celeste Ferreira‐Cornwell, Liza Squires	37
16	Efficacy and Safety of Lisdexamfetamine Dimesylate in Adolescents With Attention-Deficit/Hyperactivity Disorder 2011 ·Journal of the American Academy of Child & Adolescent Psychiatry ·Robert L. Findling, Ann Childress, Andrew J. Cutler, Maria Gasior, Mohamed Hamdani, M. Celeste Ferreira‐Cornwell, Liza Squires	101
17	Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder 2009 ·Behavioral and Brain Functions ·Lenard A. Adler, D. Wayne Goodman, Richard H. Weisler, Mohamed Hamdani, Thomas Roth	32
18	Short-Term Effects of Lisdexamfetamine Dimesylate on Cardiovascular Parameters in a 4-Week Clinical Trial in Adults With Attention-Deficit/Hyperactivity Disorder 2009 ·The Journal of Clinical Psychiatry ·Lenard A. Adler, Richard H. Weisler, D. Wayne Goodman, Mohamed Hamdani, Gwendolyn Niebler	37
19	Unusual Scotomas After Transsphenoidal Surgery of a Pituitary Macroadenoma 1997 ·Journal of Neuro-Ophthalmology ·Hélène Dollfus, (unknown), Philippe Touraine, Christophe Orssaud, Mohamed Hamdani, P Derome, F Kuttenn, Jean-Louis Dufier	1
20	Lidocaine-Clonidine Retrobulbar Block for Cataract Surgery in the Elderly 1996 ·Regional Anesthesia The Journal of Neural Blockade in Obstetrics Surgery & Pain Control ·(unknown), (unknown), Mohamed Hamdani, (unknown), (unknown)	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact